Anzeige
Mehr »
Donnerstag, 07.08.2025 - Börsentäglich über 12.000 News
Große CEO-Enthüllung: Analysten sehen +56% Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NWE | ISIN: US74638P2083 | Ticker-Symbol: 1YI
NASDAQ
06.08.25 | 19:23
2,290 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PURPLE BIOTECH LTD ADR Chart 1 Jahr
5-Tage-Chart
PURPLE BIOTECH LTD ADR 5-Tage-Chart

Aktuelle News zur PURPLE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
PURPLE BIOTECH Aktie jetzt für 0€ handeln
MiPurple Biotech Ltd. Q2 Profit Drops1
MiPurple Biotech Ltd.: Purple Biotech Reports Second Quarter 2025 Financial Results76Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms...
► Artikel lesen
MiPURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
23.07.Purple Biotech Ltd.: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025153REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek...
► Artikel lesen
23.07.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
10.07.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer2
23.06.Purple Biotech Ltd.: Purple Biotech Highlights Significant Advantages of the Novel CAPTN-3 Tri-Specific Antibody Platform at the EACR 2025 Annual Congress154REHOVOT, Israel, June 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek...
► Artikel lesen
17.06.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer5
04.06.Purple Biotech Ltd.: Purple Biotech Announces Poster Presentation at EACR 2025 on its Novel CAPTN-3 Tri-Specific Antibody Platform6
30.05.H.C. Wainwright erhöht Kursziel für Purple Biotech-Aktie auf 34 US-Dollar3
30.05.H.C. Wainwright lifts Purple Biotech stock target to $3412
21.05.Purple Biotech GAAP EPADS of -$0.172
21.05.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer2
21.05.Purple Biotech Ltd.: Purple Biotech Reports First Quarter 2025 Financial Results205Final CM24 Phase 2 data presented at AACR Annual Meeting 2025, strengthening patient selection strategy for CM24 Phase 2b study planned to be initiated in Second Half of 2025 NT219 data presented...
► Artikel lesen
12.05.Purple Biotech Appoints Shai Lankry As Chief Financial Officer1
12.05.Purple Biotech names Shai Lankry as CFO1
12.05.Purple Biotech appoints Shai Lankry as new CFO1
12.05.Purple Biotech Ltd.: Purple Biotech Appoints Shai Lankry as Chief Financial Officer256U.S.-based Lankry brings over 20 years of financial leadership in biotech and healthcare with a proven track record of driving strategic growth, operational excellence, and capital market execution...
► Artikel lesen
12.05.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
30.04.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
Weiter >>
43 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1